Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in Active Psoriatic Arthritis
NCT04882098Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2021
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 29
01
Overview
A Phase 3 trial of guselkumab in psoriatic arthritis (PsA), sponsored by Janssen Pharmaceutical. Started Jun 2021; status: active, not recruiting.
02
Drugs
guselkumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT04882098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04882098.